Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Long-Term Investments (2020 - 2023)

Oncology Institute (TOI) has disclosed Long-Term Investments for 4 consecutive years, with $58.9 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Long-Term Investments changed N/A year-over-year to $58.9 million, compared with a TTM value of $58.9 million through Jun 2023, changed N/A, and an annual FY2022 reading of $58.4 million, changed N/A over the prior year.
  • Long-Term Investments was $58.9 million for Q2 2023 at Oncology Institute, roughly flat from $58.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $230.3 million in Q1 2021 and bottomed at $58.2 million in Q3 2022.
  • Average Long-Term Investments over 4 years is $167.8 million, with a median of $230.0 million recorded in 2021.
  • The sharpest move saw Long-Term Investments rose 0.11% in 2021, then plummeted 74.69% in 2022.
  • Year by year, Long-Term Investments stood at $230.3 million in 2020, then dropped by 0.1% to $230.0 million in 2021, then tumbled by 74.63% to $58.4 million in 2022, then rose by 1.01% to $58.9 million in 2023.
  • Business Quant data shows Long-Term Investments for TOI at $58.9 million in Q2 2023, $58.8 million in Q1 2023, and $58.4 million in Q4 2022.